Information Provided By: 
Fly News Breaks for November 30, 2016
TXMD
Nov 30, 2016 | 07:39 EDT
Stifel analyst Annabel Samimy expects the Phase III trial of TherapeuticsMD's estradiol+progesterone for the treatment of vasomotor symptoms in menopausal women to show that the three highest doses of the company's drug are "efficacious." The analyst says that estradiol has successfully reduced VMS symptoms in prior trials. She keeps a $14 price target and a Buy rating on the shares.
News For TXMD From the Last 2 Days
There are no results for your query TXMD
